Empower Advisory Group LLC Sells 1,095 Shares of Bristol-Myers Squibb (NYSE:BMY)

Empower Advisory Group LLC cut its stake in Bristol-Myers Squibb (NYSE:BMY) by 11.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,179 shares of the biopharmaceutical company’s stock after selling 1,095 shares during the period. Empower Advisory Group LLC’s holdings in Bristol-Myers Squibb were worth $423,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of BMY. M&G Plc acquired a new position in Bristol-Myers Squibb during the 1st quarter worth $392,608,000. Mizuho Markets Americas LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at $11,931,000. First Foundation Advisors boosted its holdings in Bristol-Myers Squibb by 20.1% in the first quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 548 shares during the last quarter. Te Ahumairangi Investment Management Ltd increased its position in Bristol-Myers Squibb by 2.9% in the first quarter. Te Ahumairangi Investment Management Ltd now owns 149,957 shares of the biopharmaceutical company’s stock worth $8,132,000 after purchasing an additional 4,250 shares during the period. Finally, Nicolet Advisory Services LLC raised its holdings in Bristol-Myers Squibb by 62.5% during the 1st quarter. Nicolet Advisory Services LLC now owns 12,600 shares of the biopharmaceutical company’s stock worth $650,000 after purchasing an additional 4,844 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Samit Hirawat bought 1,830 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on BMY shares. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Citigroup lifted their target price on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Morgan Stanley upped their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday. Finally, Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price on the stock. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Trading Up 0.1 %

BMY opened at $58.49 on Friday. The stock has a market capitalization of $118.63 billion, a P/E ratio of -16.29, a P/E/G ratio of 21.34 and a beta of 0.44. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The firm’s fifty day simple moving average is $52.41 and its 200 day simple moving average is $47.07.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.00 earnings per share. As a group, research analysts anticipate that Bristol-Myers Squibb will post 0.92 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.10%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.